Ефективність ензимотерапії у комплексному лікуванні синдрому хронічного тазового болю при ендометріозі

The article presents the results of the treatment of chronic pelvic pain syndrome (CPPS) and associated symptoms by endometriosis with the use of the enzyme preparation of distrept-enzymes H46A: streptokinase and streptodornase (Distreptaza Distrept).The objective: to analyse the clinical effectiveness of enzyme therapy in the complex treatment of patients with CPPS which is associated with endometriosis.Materials and methods. The study included 124 patients with histologically confirmed endometriosis after surgical treatment. Patients were divided into two groups: the main group (MG) – 74 women who received hormonal therapy with gonadotropin-releasing hormone agonists in combination with distrept-enzymes H46A – streptokinase 15,000 IU and streptodornase 1,250 IU (Distreptaza Distrept), and the control group (CG) – 50 women who received only hormonal therapy without enzyme therapy. Clinical symptoms were assessed 1 month after the therapy.Results. At the specified time, there were the following results: pelvic pain was found only in 10 (13.5%) patients in the MG and 27 (54.0%) women in the CG (p < 0.001); dyspareunia – 9 (12.0%) and 23 (46.0%), respectively (p < 0.010); changes in vaginal discharges – 14 (19.0%) and 15 (30.0%); dysuria – 7 (9.5%) and 25 (50.0%), respectively (p < 0.001); dyschezia – 8 (10.8%) and 14 (28.0%), respectively (p = 0.03). No adverse effects or allergic reactions during use of enzyme therapy were observed.Conclusions. The analysis the study results showed that the use of enzyme therapy in the form of rectal suppositories of distrept-enzymes H46A: streptokinase and streptodornase (Distreptaza Distrept) in the complex treatment of CPPS which is associated with endometriosis contributes to a significant reduction in the severity of clinical manifestations of this syndrome and associated symptoms. The obtained data confirm the feasibility of including enzyme therapy in the complex treatment of patients with this pathology.